Article claims diabetes drug henagliflozin lengthened telomeres in a trial
An article reports a 26-week trial of henagliflozin in which more treated people had longer telomeres than those on placebo. The result is preliminary and needs independent verification.
Source: Post claims diabetes drug henagliflozin lengthened telomeres in a trial (x.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
According to the article, the trial was randomized and placebo-controlled, lasted 26 weeks, and used henagliflozin. At the end, 90.5% of the treated group had longer telomeres, compared with 65.6% of the placebo group (p<0.01).
Telomeres are the protective ends of chromosomes, and their length is studied as a possible marker of cellular aging. Randomized trials help compare groups fairly, but a single study rarely confirms an effect, and results may not repeat in other people. For this reason, the claim should be treated as preliminary.
What it means
If confirmed, the finding suggests an association between the drug and telomere length, but it does not prove that the drug slows aging or protects health. It is still unknown whether the effect lasts longer, applies to other groups, or leads to real clinical outcomes.
How to read it with care
A result like this does not replace a consultation. Anyone considering a change in diet, supplements or treatment should talk to a doctor or another qualified professional, and should not change medication use on their own.